川芎嗪联合瑞舒伐他汀对缺血性脑白质病变患者的保护作用

The Protective Effect of Ligustrazine Combined with Rosuvastatin on Patients with Ischemic Leukoencephalopathy

目的探讨川芎嗪联合瑞舒伐他汀治疗的缺血性脑白质病变(WMIL)患者血清中基质金属蛋白酶3(MMP3)、基质金属蛋白酶9(MMP9)、胶质纤维酸性蛋白(GFAP)及生化指标水平,探索联合用药对WMIL的潜在保护作用。方法选取2019年5月-2020年10月我院收治的并明确诊断为WMIL患者122例,将其随机分为对照组和实验组,各61例。所有患者均予以常规治疗,对照组在此基础上加用瑞舒伐他汀,实验组在对照组的基础上加用川芎嗪,比较两组血清MMP3、MMP9、GFAP、同型半胱氨酸、胱抑素C、超敏C反应蛋白、甘油三酯及胆固醇水平的差异。结果两组MMP3、MMP9、GFAP、同型半胱氨酸、超敏C反应蛋白、甘油三酯、胆固醇水平均较治疗前降低,差异有统计学意义(P<0.05);同时,实验组MMP3、MMP9、GFAP、同型半胱氨酸、超敏C反应蛋白水平低于对照组,差异有统计学意义(P<0.05)。结论川芎嗪联合瑞舒伐他汀治疗WMIL能够有效降低患者血清MMP3、MMP9、GFAP、同型半胱氨酸、超敏C反应蛋白水平,减轻炎症反应,有利于保护缺血受损的脑白质。

Objective To investigate the serum levels of matrix metalloproteinase 3(MMP3),matrix metalloproteinase 9(MMP9),glial fibrillary acidic protein(GFAP)and biochemical indexes in patients with ischemic white matter disease(WMIL)treated with ligustrazine combined with rosuvastatin level,explore the potential protective effect of combination drugs on WMIL.Methods A total of 122 patients who were admitted to our hospital from May 2019 to October 2020 and were clearly diagnosed as WMIL were randomly divided into a control group and an experimental group,each with 61 cases.All patients were given conventional treatment.The control group was given rosuvastatin on this basis,and the experimental group was given ligustrazine on the basis of the control group.The differences in serum levels of MMP3,MMP9,GFAP,homocysteine,cystatin C,high-sensitivity C-reactive protein,triglycerides and cholesterol were compared between the two groups.Results The levels of MMP3,MMP9,GFAP,homocysteine,high-sensitivity C-reactive protein,triglycerides,and cholesterol levels in the two groups were lower than before treatment,the difference was statistically significant(P<0.05);At the same time,the levels of MMP3,MMP9,GFAP,homocysteine,and high-sensitivity C-reactive protein in the experimental group were lower than those in the control group,the difference was statistically significant(P<0.05).Conclusion The combination of ligustrazine and rosuvastatin in the treatment of WMIL can effectively reduce the serum levels of MMP3,MMP9,GFAP,homocysteine,and high-sensitivity C-reactive protein,reduce inflammation,and protect the ischemic-damaged white matter.